KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacira BioSciences (PCRX) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Pacira BioSciences (PCRX) over the last 16 years, with Q3 2025 value amounting to $5.4 million.

  • Pacira BioSciences' Net Income towards Common Stockholders rose 10378.63% to $5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.4 million, marking a year-over-year increase of 12362.81%. This contributed to the annual value of -$99.6 million for FY2024, which is 33730.19% down from last year.
  • Per Pacira BioSciences' latest filing, its Net Income towards Common Stockholders stood at $5.4 million for Q3 2025, which was up 10378.63% from -$4.8 million recorded in Q2 2025.
  • In the past 5 years, Pacira BioSciences' Net Income towards Common Stockholders registered a high of $25.8 million during Q2 2023, and its lowest value of -$143.5 million during Q3 2024.
  • In the last 5 years, Pacira BioSciences' Net Income towards Common Stockholders had a median value of $9.0 million in 2024 and averaged $296631.6.
  • As far as peak fluctuations go, Pacira BioSciences' Net Income towards Common Stockholders skyrocketed by 166681.1% in 2023, and later crashed by 142129.31% in 2024.
  • Quarter analysis of 5 years shows Pacira BioSciences' Net Income towards Common Stockholders stood at -$5.1 million in 2021, then plummeted by 96.92% to -$10.1 million in 2022, then soared by 346.19% to $24.9 million in 2023, then tumbled by 35.5% to $16.0 million in 2024, then crashed by 66.14% to $5.4 million in 2025.
  • Its Net Income towards Common Stockholders stands at $5.4 million for Q3 2025, versus -$4.8 million for Q2 2025 and $4.8 million for Q1 2025.